Member Info for miavoce

Crumbs - Lindy must have known that Modi1 as a mono therapy may not achieve a cure, and equally she must also have known that Modi1 + CI could work better than Modi1 alone, hence the CI cohorts.

I think a major part of the psychology problem here is that patient 1, Trish, had such a great response that the failure to maintain this response level across other patients has has created the feeling that Modi1 has somehow failed.

In reality the achievement of Modi1 in late stage otherwise untreatable cancers is indeed very encouraging, and should the combination of CI and Modi1 be better than CI alone then Modi1 could well turn out to be a blockbuster.

I believe Lindy can see which which way this is going and she seems positive/upbeat about the Mod1+CI combination - maybe what she has seen from the SCIB1+CI has given her confidence....

WTP : This is a painful one for me to admit, but us LTH's were wrong, very wrong (obvious in hindsight)

I think you are wrong in this. I expect SCIB1 results to be good based on the messages about a clear path to market and iSCIB1 should make it even better. mAb's are looking very good with a commercial deal in the bag, another in discussion, and a new 3rd part evaluation underway. Modi1 making a real difference in Ovarian and H&N, and the CI combination study is just getting underway. And you have all this for a market cap of derisory £80m !!! Just because the market is currently absolutely rubbish doesn't mean that Scancell doesn't have huge potential which isn't far from delivering. I am very hopeful that Scancell will avoid the need for a fundraise through income from deals.

In the interview that appeared online a few weeks ago Cossery did imply that the antibody platform could be offloaded (unless I misunderstood) so perhaps the 6 month evaluation is a concrete step towards this ? It should certain solve any funding problems (I can't see it being sold for < £1bn) for many years to come and would enable the Moditope and Immunobody work to move at maximum pace.

This RNS could prove to be a slow burner for the SP as awareness of the meaning and commercial implications gradually spread and sink in. Hopefully will mark the start of a steady uptrend between now and September.

Given the emphasis of the RNS on activity is being focused on SCIB1 and Modi1, what (if anything) might this mean for other slated activities such as Mod12 prep and the in-house progression of the 2 glymabs referred to in earlier RNS's ? Have these been put on the back burner for a while or is progress continuing.

The SCIB1 + CPI data must be looking pretty good given the comments about a registration trial and potentially rapid progress towards the market. This could be a dark horse.

Maybe they aren't bothering with fluff RNS's to support the SP because they know that the forthcoming news will take care of that (assuming of course that the next wave of funds are to be raised through a share issue rather than a deal).

Do you have the recording crumbs ?

I believe you have WTP. The DTH signifies a strong T-Cell response to the vaccine.

Something something(dtc?) abbreviation = DTH Delayed Type Hypersensitivity

Very interesting that they are there. I can't imagine that they would be attending if they didn't have some interest from other parties wishing to speak to them so perhaps bodes well.

Thanks Mayo51

Hi Bermudashorts - how do you know that Scancell are attending ?

Poster published:-

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/asco_modify-study-poster_april_final-2.0x.pdf

CTC's do indeed enter the bloodstream - there are various technologies which can capture these for analysis, the best of which is Angle PLC's Parsortix system which can harvest live cancer cells from a simple blood test. These cells can then be analysed using the same technology as is used to analyse a tissue biopsy.

Blimey, I could do without RNS's with that title !! Fortunately they were just announcing that the have no relationship with SVB...phew.

Thoughts ? Usual suspect comes out with usual stuff whenever SP weakness.

Maybe their NOMAD advised caution

It wasn't just showing in IG, was also in A D V F N and I'm sure will be same in all other platforms. What makes you think it wasn't a real trade (given the price was different than the earlier 100k) ?